Association between XPC rs2228000(C/T) polymorphism and the susceptibility of breast cancer: a Metaanalysis

doi:10.3760/cma.j.issn.1673-422X.2016.10.008

Abstract

Abstract: ObjectiveTo quantitatively examine the relationship between xeroderma pigmentosum complementation C group (XPC) rs2228000(C/T) polymorphism and the susceptibility of breast cancer. MethodsThe relevant casecontrol studies published up to December 2015 which investigated XPC rs2228000(C/T) polymorphism and breast cancer risk were identified by searching PubMed, Cochrane Library, Chinese Biomedical Literature Data, Wanfang Database, China National Knowledge Infrastructure and VIP Database. Metaanalysis was conducted using STATA 12.0 software and odds ratio (OR) with its 95%CI were estimated. ResultsA total of 8 researches involving 9 casecontrol studies (3 850 breast cancer cases and 5 047 healthy controls) were included. The Metaanalysis showed that there was statistical association between XPC rs2228000(C/T) variance and breast cancer risk in the homozygous model (TT vs. CC: OR=1.28, 95%CI: 1.081.52, Z=2.80, P=0.005) and recessive model (TT vs. TC+CC: OR=1.23, 95%CI: 1.051.43, Z=2.64, P=0.008), but not in the allele model, heterozygote model and dominant model. In the subgroup of ethnicity and genotyping methods, the different significant correlation was existed between them under Asian and PCRRFLP in genetic models (T vs. C: OR=1.21, 95%CI: 1.051.40, Z=2.63, P=0.009; TT vs. CC: OR=1.55, 95%CI: 1.132.13, Z=2.70, P=0.007; TT+TC vs. CC: OR=1.26, 95%CI: 1.021.55, Z=2.19, P=0.028; TT vs. TC+CC: OR=1.39, 95%CI: 1.041.87, Z=2.23, P=0.026). We also found significant association between them in subgroup of populationbased controls in the homozygous model (TT vs. CC: OR=1.27, 95%CI: 1.021.57, Z=2.16, P=0.031). ConclusionXPC rs2228000(C/T) polymorphism may be associated with the susceptibility of breast cancer, especially in Asian, and genetype TT may increase the risk of breast cancer.

Key words: Breast neoplasms, Polymorphism, single nucleotide, Metaanalysis, Xeroderma pigmentosum complementation C group gene

Cui Jing, Tan Hui, Jiang Lei, Yuan Wenzhen, Guan Quanlin. Association between XPC rs2228000(C/T) polymorphism and the susceptibility of breast cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(10): 752-757.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI: 10.3322/caac.21254. ［3］ Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes［J］. Biochim Biophys Acta, 2015, 1856(1): 73-85. DOI: 10.1016/j.bbcan.2015.06.002. ［4］ Amir E, Seruga B, Serrano R, et al. Targeting DNA repair in breast cancer: a clinical and translational update［J］. Cancer Treat Rev, 2010, 36(7): 557-565. DOI: 10.1016/j.ctrv.2010.03.006. ［5］ Thoms KM, Kuschal C, Emmert S. Lessons learned from DNA repair defective syndromes［J］. Exp Dermatol, 2007, 16(6): 532-544. DOI: 10.1111/j.16000625.2007.00559.x. ［6］ Subba Rao K. Mechanisms of disease: DNA repair defects and neurological disease［J］. Nat Clin Pract Neurol, 2007, 3(3): 162-172. DOI: 10.1038/ncpneuro0448. ［7］ O′driscoll M, Jeggo PA. The role of doublestrand break repairinsights from human genetics［J］. Nat Rev Genet, 2006, 7(1): 45-54. DOI: 10.1038/nrg1746. ［8］吴雪铭, 马韵, 龙喜带. DNA修复基因XPC研究进展［J］. 右江民族医学院学报, 2009, 31(5): 876-878. DOI: 10.3969/j.issn.10015817.2009.05.088. ［9］ Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms［J］. DNA Repair (Amst), 2008, 7(2): 141-148. DOI: 10.1016/j.dnarep.2007.08.006. ［10］陈泽鑫, 刘慧, 潘益峰, 等. 试验性和观察性研究相关医学文献质量评价方法［J］. 中国循证医学杂志, 2011, 11(11): 1229-1236. DOI: 10.3969/j.issn.16722531.2011.11.002. ［11］ PérezMayoral J, PachecoTorres AL, Morales L, et al. Genetic polymorphisms in RAD23B and XPC modulate DNA repair capacity and breast cancer risk in Puerto Rican women［J］. Mol Carcinog, 2013, 52(Suppl 1): E127-E138. DOI: 10.1002/mc.22056. ［12］ Yang X, Liu D, Wu H, et al. Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients［J］. Cancer Sci, 2012, 103(7): 1207-1214. DOI: 10.1111/j.13497006.2012.02312.x. ［13］ Roberts MR, Shields PG, Ambrosone CB, et al. Singlenucleotide polymorphisms in DNA repair genes and association with breast cancer risk in the web study［J］. Carcinogenesis, 2011, 32(8): 1223-1230. DOI: 10.1093/carcin/bgr096. ［14］吴茵茵, 马新源, 姚开颜, 等. XPC基因Lys939Gln和Ala499Val多态性与乳腺癌易感性的关联研究［J］. 浙江大学学报(医学版), 2011, 40(3): 252-258. DOI: 10.3785/j.issn.10089292.2011.03.004. ［15］ Shen J, Gammon MD, Terry MB, et al. Xeroderma pigmentosum complementation group C genotypes/diplotypes play no independent or interaction role with polycyclic aromatic hydrocarbonsDNA adducts for breast cancer risk［J］. Eur J Cancer, 2008, 44(5): 710-717. DOI: 10.1016/j.ejca.2007.10.027. ［16］ Smith TR, Levine EA, Freimanis RI, et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk［J］. Carcinogenesis, 2008, 29(11): 2132-2138. DOI: 10.1093/carcin/bgn193. ［17］ Jorgensen TJ, Visvanathan K, Ruczinski I, et al. Breast cancer risk is not associated with polymorphic forms of xeroderma pigmentosum genes in a cohort of women from Washington County, Maryland［J］. Breast Cancer Res Treat, 2007, 101(1): 65-71. ［18］ Shen J, Desai M, Agrawal M, et al. Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer［J］. Cancer Epidemiol Biomarkers Prev, 2006, 15(9): 1614-1619. DOI: 10.1158/10559965.EPI060218. ［19］ Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005［J］. Mutat Res, 2005, 577(1/2): 275-283. DOI: 10.1016/j.mrfmmm.2005.03.007. ［20］ Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review［J］. J Natl Cancer Inst, 2000, 92(11): 874-897. ［21］ Jani′cijevi′c A, Sugasawa K, Shimizu Y, et al. DNA bending by the human damage recognition complex XPCHR23B［J］. DNA Repair (Amst), 2003, 2(3): 325-336. ［22］ Thoma BS, Vasquez KM. Critical DNA damage recognition functions of XPChHR23B and XPARPA in nucleotide excision repair［J］. Mol Carcinog, 2003, 38(1): 1-13. DOI: 10.1002/mc.10143. ［23］ Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)PDNA adducts in a sample of healthy subjects［J］. Carcinogenesis, 2001, 22(9): 1437-1445. ［24］ Wang Y, Li Z, Liu N, et al. Association between CCND1 and XPC polymorphisms and bladder cancer risk: a metaanalysis based on 15 casecontrol studies［J］. Tumour Biol, 2014, 35(4): 3155-3165. DOI: 10.1007/s1327701314129. ［25］ PaszkowskaSzczur K, Scott RJ, Górski B, et al. Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population［J］. Mol Biol Rep, 2015, 42(3): 755-764. DOI: 10.1007/s110330143824z. ［26］ PaszkowskaSzczur K, Scott RJ, SerranoFernandez P, et al. Xeroderma pigmentosum genes and melanoma risk［J］. Int J Cancer, 2013, 133(5): 1094-1100. DOI: 10.1002/ijc.28123.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.